-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

614.O1.6 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Understanding and Exploiting Molecular Therapeutic Targets in ALL

Symposia: Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, ALL, Combination therapy, Antibody Therapy, Acute Myeloid Malignancies, AML, Fundamental Science, Translational Research, Bioinformatics, Pediatric, Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunotherapy, Immunology, Lymphoid Malignancies, Computational biology, Biological Processes, Monoclonal Antibody Therapy, Technology and Procedures, Study Population, Human, Animal model, Measurable Residual Disease , Pathogenesis, Machine learning, Omics technologies
Sunday, December 8, 2024: 4:30 PM-6:00 PM
Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
Moderators:
Jan Zuna, MD, PhD, CLIP, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague and Sarah K Tasian, MD, ARRAY(0xe31f8dc)
Disclosures:
Tasian: Kura Oncology: Research Funding; Aleta Biotherapeutics: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Other: Travel support; Wugen, Inc: Membership on an entity's Board of Directors or advisory committees; Incyte Corporation: Research Funding; Amgen: Other: Travel support.
4:30 PM

Johanna Maria Horns1*, Thomas Beder2,3*, Malwine J Barz, PhD1,3*, Aeint-Steffen Ströh, MD1*, Axel Künstner, PhD4*, Sonja Bendig2,3*, Guranda Chitadze, MD, PhD3,5*, Cecilia Bozzetti, MD1*, Nikos Darzentas, PhD5*, Katharina Iben2*, Michaela Kotrova, MD, PhD5*, Martin Neumann, MD2,3*, Wiebke Weßels, PhD1*, Hauke Busch, PhD4*, Lennart Lenk, PhD6,7*, Judith S. Hecker, MD8,9*, Stefan Knop, MD10*, Boris Böll, MD11*, Johannes Duell, MD12*, Walter Fiedler, MD13, Christoph Faul, MD14, Christoph Röllig, MD, MSc15*, Bernd Spriewald, MD16*, Björn Steffen, MD17*, Maher Hanoun, MD, PhD18*, Nicola Goekbuget, MD17, Claudia D Baldus, MD2,3*, Lorenz Bastian3,19* and Monika Brüggemann, MD2,3*

1Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany
2University Medical Center Schleswig-Holstein, University Cancer Center Schleswig-Holstein, Kiel, Germany
3Clinical Research Unit CATCH ALL (KFO 5010/1) funded by the Deutsche Forschungsgemeinschaft, Kiel, Germany
4Group for Medical Systems Biology, Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
5Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany
6Department of Pediatrics I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
7Department of Pediatrics I, Pediatric Hematology and Oncology, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Kiel, Germany
8Department of Medicine III, Hematology and Oncology, Technical University of Munich (TUM), School of Medicine and Health, Munich, Germany
9TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany
10Comprehensive Cancer Center Erlangen, Klinikum Nuremberg, Nuremberg, Germany
11Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital of Cologne; equal contribution, Cologne, Germany
12University of Wurzburg, Wurzburg, Germany
13Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
14Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tübingen, Germany
15Department of Internal Medicine I, University Hospital Dresden, Dresden, Germany
16Department of Medicine 5, University Hospital of Erlangen, Erlangen, Germany
17Department of Medicine, Hematology/Oncology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany
18Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany
19Medical Department II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

4:45 PM

Ruifeng Sun1*, Jaewoong Lee, PhD1,2*, Dewan Artadji1*, Mark E Robinson, PhD1*, Kohei Kume, PhD1*, Zhangliang Cheng, BSc1*, Kadriye Nehir Cosgun, PhD1*, Lai N Chan, PhD1, Etienne Leveille, MD1*, Ning Ma, PhD3*, Huimin Geng, PhD4*, Elisabeth Paietta, PhD5*, Nagarajan Vaidehi, PhD3* and Markus Müschen, MD1

1Center of Molecular and Cellular Oncology, Yale University, New Haven, CT
2School of Biosystems and Biomedical Sciences, Korea University, Seoul, Korea, Republic of (South)
3Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA
4Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA
5Department of Oncology, Montefiore Medical Center, Bronx, NY

5:00 PM

Danielle Wolfe Cohen, MD1, Clemence Aldebert, MD2*, Emily Duan, MD3*, Sylwia Jasinski, MD4*, Xiaotu Ma, PhD5, Heather L. Mulder6*, John Easton7*, Jiyuan Hu, PhD3*, Laura E. Hogan, MD8*, David T. Teachey, MD9, Elizabeth A. Raetz, MD10, Nikki Evensen, PhD3 and William L. Carroll, MD11

1New York University Grossman School of Medicine, New York, NY
2NYU Langone Health, Laura and Isaac Perlmutter Cancer Center, New York, NY
3NYU Langone Health, New York, NY
4Department of Pediatrics, NYU Long Island School of Medicine, Mineola, NY
5St. Jude Children's Research Hospital, Memphis, TN
6St Jude Children's Research Hospital, Memphis, TN
7St. Jude Children’s Research Hospital, Memphis, TN
8Stony Brook University, Stony Brook, NY
9Division of Oncology, Children's Hospital of Philadelphia, Rutledge, PA
10Department of Pediatrics, NYU Langone Health, New York, NY
11Perlmutter Cancer Center, Department of Pediatrics and Pathology, NYU Grossman School of Medicine, New York, NY

5:15 PM

Andrew Hughes, MD, PhD1, Rawan Shraim, PhD1*, Lahari Uppuluri, PhD1*, Haley Newman, MD1, Gongping Shi, PhD2*, Julie Asare, MD3*, Theresa Ryan4*, Elizabeth A. Raetz, MD5, James A. Whitlock6, Maureen M. O'Brien, MD7, Deepa Bhojwani, MD8, Rachel E. Rau, MD9, Kara L. Davis, DO10*, Stacy Cooper11, Patrick Brown12*, Stephen P. Hunger, MD13, Mignon L. Loh, MD, PhD9, Laura E. Hogan, MD14*, Stephan A. Grupp, MD, PhD15, Jun J. Yang, PhD16, David T. Teachey, MD17 and Caroline Diorio, MD1

1Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
2Division of Oncology, Children's Hospital of Philadelphia, Philadelphia
3Johns Hopkins, Baltimore, MD
4Children's Hospital of Philadelphia, Philadelphia, PA
5Department of Pediatrics, NYU Langone Health, New York, NY
6Division of Haematology/Oncology, The Hospital for Sick Children/University of Toronto, Toronto, Canada
7Colorado Children's Hospital, Colorado
8Hematology/Oncology, Children's Hospital of Los Angeles, Los Angeles, CA
9Ben Towne Center for Childhood Cancer Research, Seattle Children’s Hospital, Fred Hutch Cancer Center, University of Washington, Seattle, WA
10Stanford University, Stanford, CA
11Johns Hopkins University, Baltimore, MD
12Bristol Myers Squibb, Princeton, NJ
13Division of Oncology, Childrens Hospital of Philadelphia, Philadelphia
14Stony Brook University, Stony Brook, NY
15Children’s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
16Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
17Division of Oncology, Children's Hospital of Philadelphia, Rutledge, PA

5:30 PM

Vojen Sadílek, MD, MSc1*, Barbora Cabalkova2*, Aneta Skotnicova2*, Michaela Reiterova2*, Martina Vaskova2*, Marketa Zaliova2*, Ondrej Hrusak2*, Jan Trka2, Tomas Kalina2*, Eva Fronkova2*, Ester Mejstrikova2* and Jan Stuchly2*

1CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, AL, Czech Republic
2CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic

5:45 PM

Anna Dietterle1*, Julia Heymann1*, Anna Laqua2*, Claas Reimer1*, Denny Takudzwa Mahachi1*, Carina Lynn Gehlert, PhD3*, Dorothee Winterberg, PhD3*, Maja Kowol4*, Alexander Arthur Wurm5,6*, Philipp Fanter1*, Denis Pinkle1*, Dennis Das Gupta7*, Christian Vokuhl8*, Jan Philipp Schmid9*, Matthias Peipp, PhD3*, Martin Schrappe, MD1, Irène Baccelli10*, Nicolas Poirier10*, Monika Brüggemann, MD2*, Gunnar Cario, MD1*, Denis Martin Schewe6* and Lennart Lenk, PhD1*

1Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Kiel, Germany
2Department of Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany, Kiel, Germany
3Division of Antibody-Based Immunotherapy, Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
4Section for Stem Cell Transplantation and Immunotherapy, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Kiel, Germany
5Mildred Scheel Early Career Center, NCT/UCC Dresden, Dresden, Germany
6Department of Pediatric Hematology and Oncology, University Hospital Dresden, Dresden, Germany, Dresden, Germany
7Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany, Kiel, Germany
8Section of Pediatric Pathology, Department of Pathology, University Hospital Bonn, Bonn, Germany, Bonn, Germany
9Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Munich, Feodor-Lynen-Str. 21, Munich, 81377, Germany, Munich, Germany
10OSE Immunotherapeutics, Nantes, France, Nantes, France

*signifies non-member of ASH